Design Therapeutics (DSGN) Cash & Current Investments (2020 - 2026)

Design Therapeutics has reported Cash & Current Investments for 7 years, with the latest figure at $207.4 million in Q2 2026.

• Cash & Current Investments for Q2 2026 came in at $207.4 million, down 4.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $207.4 million (down 4.11% YoY), and the FY2025 annual result was $219.8 million, down 10.44% from the prior year.
• Cash & Current Investments eased to $207.4 million in Q2 2026, from $222.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $371.2 million in Q1 2022 and troughed at $206.0 million in Q3 2025.
• A 5-year average of $273.9 million and a median of $265.9 million in 2024 frame the typical range for Cash & Current Investments.
• The widest annual swing landed in 2025, when Cash & Current Investments retreated 18.93%; it then retreated 2.98% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $330.4 million in 2022, then declined by 14.71% to $281.8 million in 2023, then fell by 12.89% to $245.5 million in 2024, then retreated by 10.44% to $219.8 million in 2025, then decreased by 5.66% to $207.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $207.4 million in Q2 2026, $222.8 million in Q1 2026, and $219.8 million in Q4 2025.